Document Detail


Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in atrial fibrillation.
MedLine Citation:
PMID:  21247007     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Atrial fibrillation is the most prevalent clinically relevant arrhythmia; a major cause of morbidity and hospitalization. Additionally, atrial fibrillation carries a significant risk of thrombo-embolic events, specifically cerebrovascular accident. Among the most prevalent risk factors for atrial fibrillation, hypertension not only has the strongest correlation but is also the most prevalent. The renin-angiotensin-aldosterone system represents a prime target for the treatment of hypertension through the use of angiotensin-converting enzymes inhibitors and angiotensin II receptor blockers. In addition to blood pressure control, these medications have been shown to reduce the occurrence of atrial fibrillation. They have been shown to have effects at the cellular level in preventing atrial fibrosis. Additionally, these medications may prevent the development ofatrial fibrillation, reduce the duration of atrial fibrillation, and facilitate electrical cardioversion in patients with the arrhythmia. Therefore, patients with, or at risk for atrial fibrillation may benefit from treatment with renin-angiotensin-aldosterone system antagonists; deriving benefits from these medications beyond simple blood pressure control.
Authors:
M J Levine; P Schweitzer
Related Documents :
18232997 - Sound velocity and absorption measurements under high pressure using picosecond ultraso...
6739237 - Lingual vibrotactile perception: lingual pressure effects on neuro-sensory response.
7405837 - Detection of entrapped intracardiac air with intraoperative echocardiography.
13987677 - A study of normal heart sounds, heart size, arterial pressure and electrocardiograms fr...
12570927 - Fullerene derivative attenuates ischemia-reperfusion-induced lung injury.
19521417 - Noninvasive indices of arterial stiffness in hemodialysis patients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Vnitr̆ní lékar̆ství     Volume:  56     ISSN:  0042-773X     ISO Abbreviation:  Vnitr Lek     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2011-01-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0413602     Medline TA:  Vnitr Lek     Country:  Czech Republic    
Other Details:
Languages:  eng     Pagination:  1138-41     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Department of Medicine, Beth Israel Medical Center, New York, NY, USA. mlevine@chpnet.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth, mortality and reproduction of the blue tilapia Oreochromis aureus (Perciformes: Cichlidae) i...
Next Document:  Veterinary nursing in South Africa (1977-2000).